Group CBT for Depression and AOD Disorders

Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01154309

Acronym

BRIGHT2

Enrollment

Registered

2010-06-30

Start date

2006-09-30

Completion date

2009-09-30

Last updated

2011-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Substance Use

Keywords

Depression, Substance Use, Group Cognitive Behavioral Therapy

Brief summary

The investigators will adapt and test an existing treatment (group CBT for depression) for use in outpatient substance use treatment settings as delivered by trained substance use counselors. The investigators expect that treatment will lead to improved depression and substance use outcomes.

Detailed description

Aim 1. To adapt an existing group therapy (CBT for depression), creating a manualized treatment and accompanying implementation measures and tools for use with clients with persistent depressive symptoms and AOD disorders and to obtain preliminary assessments of the treatment from patient and provider perspectives. Aim 2. To conduct a pilot test of the revised treatment in which we (a) demonstrate that when the therapy is implemented with fidelity, clinically significant reductions in depressive symptoms and AOD use occur; (b) estimate the likely effect size; and (c) investigate the underlying mechanisms of change, including both cognitive-behavioral and group processes and their relationship to depression and AOD treatment outcomes.

Interventions

BEHAVIORALGroup CBT for Depression and AOD Disorders

18 sessions of 2-hour group CBT

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Enrolled in outpatient substance abuse program * BDI II score \>13 * Probable alcohol or substance use problem

Exclusion criteria

* Cognitive impairment (Short Blessed \> 10) * Probably bipolar or schizophrenic disorder

Design outcomes

Primary

Measure	Time frame
Reductions in depressive symptoms as measured by the BDI II	Post treatment
Reductions in AOD use	Post treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026